SCHEMBL8564331

SCHEMBL8564331

Cc1ccc2c(c1)[nH]c(=O)c1cccn12

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 1/20 0.68
PARP1 P09874 15/20 0.65
CDC7 O00311 2/20 0.51
PLK4 O00444 2/20 0.51
MAPK13 O15264 2/20 0.51
PDPK1 O15530 2/20 0.51
DYRK3 O43781 2/20 0.51
ERBB2 P04626 2/20 0.51
PRKCG P05129 2/20 0.51
ROS1 P08922 2/20 0.51
KIT P10721 2/20 0.51
SRC P12931 2/20 0.51
PHKG2 P15735 2/20 0.51
AKT1 P31749 2/20 0.51
AKT2 P31751 2/20 0.51
MATK P42679 2/20 0.51
MAPKAPK2 P49137 2/20 0.51
BLK P51451 2/20 0.51
IRAK1 P51617 2/20 0.51
NEK4 P51957 2/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9415645 0.87 PARP1 (0.65) TP53PARP1CDC7PLK4MAPK13
SCHEMBL8569594 0.81 TP53 (0.68) TP53PARP1CDC7PLK4MAPK13
SCHEMBL30902522 0.81 TP53 (1.00) TP53PARP1CDC7PLK4MAPK13
SCHEMBL9415217 0.81 TP53 (0.68) TP53PARP1CDC7PLK4MAPK13
SCHEMBL13082234 0.81 TP53 (0.68) TP53PARP1CDC7PLK4MAPK13
SCHEMBL4529420 0.81 TP53 (0.68) TP53PARP1CDC7PLK4MAPK13
SCHEMBL8569221 0.80 TP53 (0.62) TP53PARP1CDC7PLK4MAPK13
SCHEMBL3796255 0.80 TP53 (0.62) TP53PARP1CDC7PLK4MAPK13
Hydrochloric Acid SCHEMBL9415725 0.79 TP53 (0.66) TP53PARP1CDC7PLK4MAPK13
SCHEMBL1133601 0.79 PARP1 (1.00) TP53PARP1CDC7PLK4MAPK13

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090238761-A1 Novel Aryl Piperazine Derivatives With Medical Utility UNIVERSITA DEGLI STUDI DI SIENA (IT) 2009-09-24 US disclosed
US-20090238761-A1 Novel Aryl Piperazine Derivatives With Medical Utility UNIVERSITA DEGLI STUDI DI SIENA (IT) 2009-09-24 US disclosed
EP-0623620-B1 5-HT3 Pyrrolopyrazine derivatives ADIR (FR) 1998-09-09 EP disclosed
US-5599812-A ANTISEROTONINE AGENTS ADIR ET COMPAGNIE (FR) 1997-02-04 US disclosed
EP-0623620-A1 5-HT3 Pyrrolopyrazine derivatives ADIR ET COMPAGNIE (FR) 1994-11-09 EP disclosed
EP-0584487-A2 4,5-Dihydro-4-oxopyrrolo (1,2-a) quinoxalines and aza-analoges and process for their preparation ASTA Medica Aktiengesellschaft (DE) 1994-03-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090238761-A1 Novel Aryl Piperazine Derivatives With Medical Utility HTR2C, HTR2A, DRD2 TP53 4710/4885PARP1 3197/4885CDC7 4759/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.